Comparison of chronic diseases in deceased and survived patients with COVID-19 admitted to the hospital

Chronic diseases in COVID-19

Authors

  • Farhang Babamahmoodi Department of Infectious Disease, Antimicrobial Resistance Research Center, School of Medicine, Razi Teaching Hospital, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran https://orcid.org/0000-0003-4239-9569
  • Lotfollah Davoodi Department of Infectious Disease, Antimicrobial Resistance Research Center, School of Medicine, Razi Teaching Hospital, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran https://orcid.org/0000-0001-7298-7789
  • Fatemeh Ahangarkani Department of Infectious Disease, Antimicrobial Resistance Research Center, School of Medicine, Razi Teaching Hospital, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran https://orcid.org/0000-0002-3629-7446
  • Aliasghar Rezaei Department of Infectious Disease, Antimicrobial Resistance Research Center, School of Medicine, Razi Teaching Hospital, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran https://orcid.org/0000-0003-3904-3123

DOI:

https://doi.org/10.22122/cdj.v11i4.666

Keywords:

COVID-19, Chronic Disease, SARS-CoV-2, Pandemic

Abstract

BACKGROUND: Assessing the prevalence of chronic diseases is necessary to reduce complications and mortality rates in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to evaluate the chronic diseases in patients with coronavirus disease 2019 (COVID-19) and describe the clinical course of symptoms and changes in laboratory findings during the hospitalization of these patients.

METHODS: This cross-sectional and retrospective study investigated the frequency of various chronic diseases in hospitalized patients with COVID-19, and compared them to deceased and improved patients in Razi Teaching Hospital, Ghaemshahr, Mazandaran Province, the northern part of Iran, during the March to September 2020. Data analysis was performed by SPSS -21 using mean and standard deviation (SD) and chi-square test .

RESULTS: 1000 patients were evaluated for chronic diseases. The most common chronic disease in patients with COVID-19 was diabetes (30.3%), followed by hypertension (HTN) (28.8%), and ischemic heart disease (IHD) (14.7%). Other chronic illnesses were less than the mentioned diseases including hypothyroidism (4.9%), heart failure (HF) (4.3%), renal failure (4.3%), obesity (2.3%), and corticosteroid consumption (2.1%).

CONCLUSION: According to the results, chronic diseases such as diabetes, HTN, and cardiovascular disorders can increase the risk of mortality from COVID-19. The mortality rate in the present study was similar to the majority of studies in this field. However, the difference in mortality rates with other studies may be because patients who required advanced medical care in the hospital and had an advanced stage of the disease were examined in our study.

References

Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020; 26(7): 1017-32.

Momtazmanesh S, Samieefar N, Uddin LQ, Ulrichs T, Kelishadi R, Roudenok V, et al. Socialization during the COVID-19 pandemic: The role of social and scientific networks during social distancing. Adv Exp Med Biol. 2021; 1318: 911-21.

Khazeei Tabari MA, Iranpanah A, Bahramsoltani R, Rahimi R. Flavonoids as promising antiviral agents against sars-cov-2 infection: A mechanistic review. Molecules. 2021; 26(13).

Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care. 2020; 24(1): 179.

Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ. 2020; 369: m1985.

Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020; 28(7): 1195-9.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061-9.

Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int J Infect Dis. 2020; 94: 91-5.

Roca-Ho H, Riera M, Palau V, Pascual J, Soler MJ. Characterization of ACE and ACE2 expression within different organs of the NOD mouse. Int J Mol Sci. 2017; 18(3).

Rao S, Lau A, So HC. exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: A Mendelian randomization analysis highlights tentative relevance of diabetes-related traits. Diabetes Care. 2020; 43(7): 1416-26.

Fernandez C, Rysa J, Almgren P, Nilsson J, Engstrom G, Orho-Melander M, et al. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. J Intern Med. 2018; 284(4): 377-87.

Maddaloni E, Buzzetti R. Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab Res Rev. 2020; 36(7): e33213321.

Marjot T, Webb GJ, Barritt AS, Moon AM, Stamataki Z, Wong VW, et al. COVID-19 and liver disease: Mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021; 18(5): 348-64.

Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Elife. 2020; 9.

Park JE, Jung S, Kim A, Park JE. MERS transmission and risk factors: A systematic review. BMC Public Health. 2018; 18(1): 574.

Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020; 36(7): e3319.

Talebi S, Nematshahi M, Tajabadi A, Khosrogerdi A. Comparison of clinical and epidemiological characteristics of deceased and recovered patients with COVID-19 in Sabzevar, Iran. J Mil Med. 2020; 22(6): 509-16.

Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020; 80(4): 388-93.

Chen X, Hu W, Ling J, Mo P, Zhang Y, Jiang Q, et al. Hypertension and diabetes delay the viral clearance in COVID-19 patients. MedRxiv. 2020.

Li X, Wang L, Yan S, Yang F, Xiang L, Zhu J, et al. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020; 94: 128-32.

Jalali SF, Ghassemzadeh M, Mouodi S, Javanian M, Akbari KM, Ghadimi R, et al. Epidemiologic comparison of the first and second waves of coronavirus disease in Babol, North of Iran. Caspian J Intern Med. 2020; 11(Suppl 1): 544-50.

Babamahmoodi F, Ahangarkani F, Yazdani charati J, Alikhani A, Hatami M, Delavaryan L, et al. Comparing clinical and para-clinical findings and risk factors among COVID-19 survived and deceased patients in North of Iran, 2019-2020. J Mazandaran Univ Med Sci. 2021; 31(201): 70-82.

Downloads

Published

2023-10-14

How to Cite

1.
Babamahmoodi F, Davoodi L, Ahangarkani F, Rezaei A. Comparison of chronic diseases in deceased and survived patients with COVID-19 admitted to the hospital: Chronic diseases in COVID-19. Chron Dis J. 2023;11(4):208–214.

Issue

Section

Original Article(s)